Belgium· BE-AMP-SAM661784-00
Litfulo 50 mg
A ritlecitinib product containing ritlecitinib tosylate, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 16 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ritlecitinib is registered in 16 of 19 countries.
Countries holding a registration under ATC L04AF08 (ritlecitinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Ritlecitinib · ATC L04AF08
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ritlecitinib Tosylate
- Manufacturer
- Pfizer Europe MA
- Country
- Belgium (BE)
- ATC code
- L04AF08
- ATC class
- Ritlecitinib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb4769006
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ritlecitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLitfuloU.S. Pharmaceuticals
- CzechiaLITFULOPfizer Europe MA EEIG, Bruxelles
- SpainLITFULO 50 MG CAPSULAS DURASPfizer Europe Ma Eeig
- FinlandLitfuloPfizer Europe MA EEIG
- FranceLITFULO 50 mg, gélulePFIZER EUROPE MA EEIG (BELGIQUE)
- United KingdomLitfulo 50mg capsulesPfizer Ltd
- CanadaLITFULOPFIZER CANADA ULC
- IcelandLitfuloPfizer Europe MA EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Litfulo
- Liechtenstein · Litfulo
- Norway · Litfulo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/59ba3731-d3da-4536-9d96-3ef717e4b712 GET /v1/drugs/59ba3731-d3da-4536-9d96-3ef717e4b712?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Litfulo 50 mg",
"name_fr": "Litfulo 50 mg",
"name_nl": "Litfulo 50 mg",
"amp_code": "SAM661784-00",
"strengths": [
"50.0000",
"50.0000",
"21.2700",
"21.2700"
],
"pack_count": 3,
"substances": [
"Ritlecitinib Tosylate",
"Ritlecitinib",
"Lactose Monohydrate",
"Potassium Hydroxide",
"Propylene Glycol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ritlecitinib",
"authorisation_numbers": [
"EU/1/23/1755/001",
"EU/1/23/1755/002",
"EU/1/23/1755/003"
]
}See everything about ritlecitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.